Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation

Background and purpose Preventing relapse by immunosuppressants (ISs) is critical for the prognosis of neuromyelitis optica spectrum disorder (NMOSD); however, the optimal duration of IS treatment is still under discussion. The objective was to explore the optimal duration of IS treatment and the ri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of neurology 2022-09, Vol.29 (9), p.2792-2800
Hauptverfasser:	Li, Rui, Li, Cong, Huang, Qiao, Liu, Zifeng, Chen, Jingjing, Zhang, Bingjun, Liu, Chunxin, Shu, Yaqing, Wang, Yuge, Kermode, Allan G., Qiu, Wei
Format:	Artikel
Sprache:	eng
Schlagworte:	drug discontinuation immunosuppressant treatment Immunosuppressive agents Inflammatory diseases longitudinal extensive transverse myelitis Myelitis Neuromyelitis neuromylitis optica spectrum disorder Patients relapse Risk Rituximab Spinal cord
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!